Loading company
Cellyan Biotechnology Co., Ltd
HKPD · Nasdaq · ·
$0.11+1.1%Sep 29 close
- 1M
- -68.1%
- 6M
- -80.2%
- 1Y
- -92.5%
Cellyan Biotechnology Co., Ltd is the 11th largest of 11 graded companies. Showing 5 of them, including HKPD itself.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Mckesson CorporationMCK | A | $100.9B | $411B | 1.1% | $6.4B | 23.19 |
| Cencora, Inc.COR | A | $58.7B | $332.8B | 0.8% | $4.1B | 22.83 |
| Cardinal Health, Inc.CAH | A | $52.1B | $254.2B | 0.7% | $4.5B | 30.98 |
| Henry Schein, Inc.HSIC | B | $9.5B | $13.6B | 3.0% | $569M | 24.78 |
| Cellyan Biotechnology Co., LtdHKPD | C- | $1.8M | $16.4M | -4.3% | $499.3K | — |
6 more medical distribution companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Cellyan Biotechnology Co., Ltd on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
HKPD · Nasdaq · ·
$0.11+1.1%Sep 29 close